Futibatinib Patent Expiration
Futibatinib is used for treating intrahepatic cholangiocarcinoma. It was first introduced by Taiho Oncology Inc
Futibatinib Patents
Given below is the list of patents protecting Futibatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lytgobi | US11833151 | Pharmaceutical composition including sodium alkyl sulfate | Nov 05, 2039 | Taiho Oncology |
| Lytgobi | US10434103 | Crystal of 3,5-disubstituted benzene alkynyl compound | Mar 31, 2036 | Taiho Oncology |
| Lytgobi | US9108973 | 3,5-disubstituted alkynylbenzene compound and salt thereof | Feb 13, 2033 | Taiho Oncology |
Futibatinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Futibatinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Taiho Oncology, Inc. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Taiho Oncology, Inc. | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications | Boundless Bio, Inc. | NA |
TERMINATED
(Jun 1, 2026)
| PHASE1 |
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Northwestern University | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE1 |